



M PHARMACEUTICAL TO PRESENT AT EQUITIES PITCH IN NEW YORK

VANCOUVER, B.C., CANADA (28 September 2015) - **M Pharmaceutical, Inc.** (CSE:MQ, OTCQB: MPHMF, FWB:T3F2), (the "**Company**"), a clinical-stage company developing innovative technologies for the monitoring and treatment of obesity, diabetes, and other gastroenterological indications, today announced that the Company will present at the Fall Equities Pitch Party at Opia Restaurant in New York City on October 1, 2015.

Matthew B. Lehman, the Company's Chief Executive Officer, will provide a corporate overview and development update on Company's technology. This will be a strong opportunity for the Company to showcase its development plan to a targeted audience of institutional and qualified investors. A copy of Mr. Lehman's presentation will be made available on the Company's website prior to the event.

About Fall Equities Pitch Party

Equities Pitch, a division of **EquitiesWorld**, is a specialized event arm designed to bring innovative companies and savvy audiences together. Equities Pitch is quarterbacked by a team of experienced venture capitalists and startup gurus that combine their networks to create the best pitch parties. Presenting companies typically come from a variety of industries including (but not limited to): biotechnology, technology, energy, mining, oil and gas, financial services and more.

About M Pharmaceutical Inc.

Formed in early 2015, **M Pharmaceutical Inc.** is a clinical-stage company developing innovative technologies for the monitoring and treatment of obesity, diabetes, and other gastroenterological indications. The Company has exclusive rights to three technologies: (1) **Trimeo** capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity; (2) **Trimtec**, gastrointestinal neurostimulators implanted laparoscopically for the treatment of obesity and gastroparesis without permanent anatomical modification of the stomach; and (3) **eMosquito** wearable blood monitor, for automatic and autonomous monitoring of blood glucose by diabetics.

M Pharmaceutical trades on the Canadian Securities Exchange (CSE) under the ticker symbol "MQ" as well as on the OTCQB as "MPHMF" and FWB (Frankfurt Stock Exchange) as "T3F2."

For more information contact:

Investor Relations
Phone: +1 604 428 0511
info@m-pharma.ca
www.m-pharma.ca

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the commercialization of the rights to the

eMosquito, Trimeo and Trimtec biomedical technologies. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com and the Company's filings to the CSE at www.cnsx.ca. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.

Notice regarding investigational devices: Trimeo, Trimtec, and eMosquito are investigational devices and are not currently available outside of approved clinical trials. Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.